Lakewood-Amedex Biotherapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Lakewood-Amedex Biotherapeutics Inc. focuses on discovery, development, and commercialization of fast-acting broad-spectrum antimicrobials to treat infectious diseases and combat antibiotic-resistant bacteria. The company develops a novel Bisphosphocin® class of antimicrobial compounds and related topical formulations designed for local delivery at infection sites, with a lead program addressing mildly infected diabetic foot ulcers. Lakewood-Amedex operates as a clinical-stage biotechnology company, pursuing exploratory and later-stage clinical trials to establish safety and efficacy, aiming to reduce infection burden and resistance threats in clinical settings. The business is organized around pharmaceutical research and development, with a pipeline of antimicrobial candidates including Nu-3 and related derivatives, and a strategy that emphasizes partnerships, strategic collaborations, and potential regulatory advancement to support commercialization. Lakewood-Amedex is headquartered in Sarasota, Florida, United States, and targets global markets through partnerships and potential distribution channels, with ongoing IP protection through a portfolio of patent applications covering its Bisphosphocin® technology and antimicrobial compositions. The company positions itself within the infectious disease therapeutics segment, focusing on hospital and clinical use cases where topical or localized antimicrobial intervention can mitigate systemic antibiotic exposure and resistance development. Founding year and historical context reflect its emergence as a specialized biotech focused on next-generation antimicrobials; the organization maintains a lean clinical development footprint while seeking capital-market opportunities and strategic alliances to accelerate clinical progression and potential market entry. Lakewood-Amedex maintains interest in leveraging its proprietary platform across additional infection etiologies, with plans for Phase 2a safety and dose-response studies and subsequent Phase 2b dose-comparison trials to optimize regimens ahead of larger pivotal trials. The company’s disclosures indicate a focus on product development timelines, IP strategy, and potential future commercialization, contingent on successful clinical outcomes and regulatory approvals.
Company News
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Stock Short Interest Jumps 146.8%
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. Actinium Pharmaceuticals (NYSE:ATNM) Financial Contrast
Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. MBX Biosciences (NASDAQ:MBX) Critical Survey
Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel
Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D.
Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections
Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum
Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers
Lakewood-Amedex Stock Falls Despite Positive Nu-3 Manufacturing Update
Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3